Department of Health and Social Care

Non-tuberculous Mycobacteria: Medical Treatments

Steve McCabe: To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of access to innovative treatments for people living with non-tuberculosis mycobacteria in the UK.

Will Quince: On 20 October 2022, NHS England published clinical commissioning policy on the use of nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease NTMPD, following an independent review. NHS England concluded that there was enough evidence to make the treatment available.